Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Chunling ZengLi ZhuXiaona JiaYuzhi PangZhang LiXiaojing LuFeifei XieLili DuanYuexiang WangPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)
Dasatinib shows efficacy in cancer models, inhibiting a wide range of oncogenic primary and drug-resistant KIT mutants. These results have implications for the further development of dasatinib precision therapy in GIST patients.
Keyphrases
- drug resistant
- multidrug resistant
- acinetobacter baumannii
- end stage renal disease
- chronic myeloid leukemia
- chronic kidney disease
- ejection fraction
- newly diagnosed
- papillary thyroid
- peritoneal dialysis
- prognostic factors
- signaling pathway
- stem cells
- transcription factor
- wild type
- bone marrow
- cell therapy
- lymph node metastasis
- smoking cessation